Vanderlaan M - Search Results

1

Engineering upper hinge improves stability and effector function of a human IgG1.

Yan B, Boyd D, Kaschak T, Tsukuda J, Shen A, Lin Y, Chung S, Gupta P, Kamath A, Wong A, Vernes JM, Meng GY, Totpal K, Schaefer G, Jiang G, Nogal B, Emery C, Vanderlaan M, Carter P, Harris R, Amanullah A. Yan B, et al. Among authors: vanderlaan m. J Biol Chem. 2012 Feb 17;287(8):5891-7. doi: 10.1074/jbc.M111.311811. Epub 2011 Dec 27. J Biol Chem. 2012. PMID: 22203673 Free PMC article.

2

Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu ZJ, Shen A, Vanderlaan M, Song A. Chung S, et al. Among authors: vanderlaan m. MAbs. 2012 May-Jun;4(3):326-40. doi: 10.4161/mabs.19941. Epub 2012 Apr 26. MAbs. 2012. PMID: 22531441 Free PMC article.

3

Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.

Wang Y, Fei D, Vanderlaan M, Song A. Wang Y, et al. Among authors: vanderlaan m. Angiogenesis. 2004;7(4):335-45. doi: 10.1007/s10456-004-8272-2. Epub 2005 May 9. Angiogenesis. 2004. PMID: 15886877

4

Host cell proteins in biotechnology-derived products: A risk assessment framework.

de Zafra CL, Quarmby V, Francissen K, Vanderlaan M, Zhu-Shimoni J. de Zafra CL, et al. Among authors: vanderlaan m. Biotechnol Bioeng. 2015 Nov;112(11):2284-91. doi: 10.1002/bit.25647. Epub 2015 Jun 16. Biotechnol Bioeng. 2015. PMID: 26010760

5

Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product.

Vanderlaan M, Maniatis A, Olney R, Rahmaoui A, Yau L, Quarmby V, Azzolino C, Woods C, Moawad D. Vanderlaan M, et al. Clin Pharmacol Ther. 2020 Apr;107(4):988-993. doi: 10.1002/cpt.1694. Epub 2019 Dec 11. Clin Pharmacol Ther. 2020. PMID: 31628764 Free PMC article. Clinical Trial.

6

Trace level analysis of leached Protein A in bioprocess samples without interference from the large excess of rhMAb IgG.

Zhu-Shimoni J, Gunawan F, Thomas A, Vanderlaan M, Stults J. Zhu-Shimoni J, et al. Among authors: vanderlaan m. J Immunol Methods. 2009 Feb 28;341(1-2):59-67. doi: 10.1016/j.jim.2008.10.015. Epub 2008 Nov 27. J Immunol Methods. 2009. PMID: 19041317

7

Performance comparison of protein A affinity-chromatography sorbents for purifying recombinant monoclonal antibodies.

Fahrner RL, Whitney DH, Vanderlaan M, Blank GS. Fahrner RL, et al. Among authors: vanderlaan m. Biotechnol Appl Biochem. 1999 Oct;30(2):121-8. Biotechnol Appl Biochem. 1999. PMID: 10512791

8

Experience with host cell protein impurities in biopharmaceuticals.

Vanderlaan M, Zhu-Shimoni J, Lin S, Gunawan F, Waerner T, Van Cott KE. Vanderlaan M, et al. Biotechnol Prog. 2018 Jul;34(4):828-837. doi: 10.1002/btpr.2640. Epub 2018 May 10. Biotechnol Prog. 2018. PMID: 29693803 Review.

9

A two-dimensional protein map of Chinese hamster ovary cells.

Champion KM, Arnott D, Henzel WJ, Hermes S, Weikert S, Stults J, Vanderlaan M, Krummen L. Champion KM, et al. Among authors: vanderlaan m. Electrophoresis. 1999 Apr-May;20(4-5):994-1000. doi: 10.1002/(SICI)1522-2683(19990101)20:4/5<994::AID-ELPS994>3.0.CO;2-N. Electrophoresis. 1999. PMID: 10344277

10

Host cell protein testing by ELISAs and the use of orthogonal methods.

Zhu-Shimoni J, Yu C, Nishihara J, Wong RM, Gunawan F, Lin M, Krawitz D, Liu P, Sandoval W, Vanderlaan M. Zhu-Shimoni J, et al. Among authors: vanderlaan m. Biotechnol Bioeng. 2014 Dec;111(12):2367-79. doi: 10.1002/bit.25327. Epub 2014 Sep 10. Biotechnol Bioeng. 2014. PMID: 24995961 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters